Substantial price increases for certain drugs gain turned the highlight on industry figures like Martin Shkreli, sparked concerns about the commerce model of drug company Valeant Pharmaceuticals and triggered Congressional probes. A hearing by the House Oversight and Government Reform Committee on Thursday was watched closely not only by those following the outspoken Mr. Shkreli but many wondering if Congress or regulators might take action to curb drug-price gouging.
Source: wsj.com